Key result
Higher TMAO levels linked to ~2% higher odds of coronary thrombus burden in STEMI.
Why the study?
STEMI is frequently associated with high coronary thrombus burden which adversely affects therapeutic success and prognosis, and biomarkers predicting thrombus burden are needed.
Are plasma NGAL and TMAO levels associated with coronary thrombus burden in patients with ST-elevation myocardial infarction?
Cross-Sectional (n=63)
Are plasma NGAL and TMAO levels associated with coronary thrombus burden in patients with ST-elevation myocardial infarction?
Plasma TMAO levels, but not NGAL, are significantly associated with and independently predict coronary thrombus burden in patients with STEMI, suggesting TMAO's potential as a biomarker for early thrombotic risk stratification.
Answers are grounded in this paper and cite their sources.
NGAL and TMAO may associate with thrombus burden in STEMI; hypothesis-generating and requires prospective validation before any clinical role.
Background and Aims ST-elevation myocardial infarction (STEMI) represents the most severe manifestation of acute coronary syndromes and is frequently associated with a high coronary thrombus burden, which adversely affects therapeutic success and clinical prognosis. Biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) and trimethylamine N-oxide (TMAO) have emerged as potential predictors of thrombus burden. This study aims to investigate the association between plasma NGAL and TMAO levels and coronary thrombus burden in patients with STEMI. Methods This cross-sectional study enrolled patients with STEMI undergoing coronary angiography. Plasma NGAL and TMAO levels were measured from venous blood samples, while coronary thrombus burden was assessed angiographically using the TIMI thrombus grading system. Results Among 63 patients with ST-elevation myocardial infarction, plasma TMAO levels were significantly higher in the high thrombus burden group than in the low thrombus burden group (93.0 ± 27.2 vs. 73.3 ± 32.5 ng/mL; p = 0.011) and independently predicted thrombus burden (OR 1.022; p = 0.025). In contrast, NGAL levels did not differ significantly between groups (median 93 vs. 98 ng/mL; p = 0.145), although a weak inverse correlation between NGAL and TMAO was observed (r = −0.280; p = 0.026). Conclusion In patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention, plasma TMAO levels were significantly associated with and independently predicted coronary thrombus burden, whereas NGAL showed no significant predictive value. TMAO may serve as a useful non-invasive biomarker for early thrombotic risk stratification in STEMI, while NGAL primarily reflects inflammatory processes rather than thrombus severity.Table 1a.Pulmonary Function Parameters Before and After Intervention in Patients with Acyanotic CHD with Left-to-Right Shunt, 1b.
No takes yet. Share an insight, caveat, or question.
Syafri et al. (2026) conducted a cross-sectional in ST-elevation myocardial infarction (n=63). Plasma TMAO and NGAL levels was evaluated on Coronary thrombus burden assessed by TIMI thrombus grading system (OR 1.022, p=0.025). Higher plasma TMAO levels independently predicted increased coronary thrombus burden in patients with STEMI (OR 1.022; P=0.025), whereas NGAL levels showed no significant predictive value.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: